PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1821
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

PD-L1 Expression by Tumor Cell-Lines: A Predictive Marker in Melanoma

Experimental Dermatology
BiochemistryDermatologyMolecular Biology
2018English

P2.06-37 Four Immunohistochemical Assays to Measure the PD-L1 Expression in Malignant Pleural Mesothelioma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Regorafenib Promotes Anti-Tumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2019English

PD-L1 Expression in Inflammatory Myofibroblastic Tumors

Modern Pathology
Forensic MedicinePathology
2018English

Melanoma-Specific MHC-II Expression Represents a Tumour-Autonomous Phenotype and Predicts Response to Anti-Pd-1/Pd-L1 Therapy

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2016English

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD-L1 Expression in Triple-Negative Breast Cancer

Cancer immunology research
Cancer ResearchImmunology
2014English

Nuclear IRF-1 Expression as a Mechanism to Assess “Capability” to Express PD-L1 and Response to PD-1 Therapy in Metastatic Melanoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2017English

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated With Checkpoint Blockade

Cancer immunology research
Cancer ResearchImmunology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy